Global Monoclonal Antibodies Drug Market

Monoclonal Antibodies Drug Comprehensive Study by Application (Oncology, Autoimmune, Inflammatory Diseases, Respiratory Diseases, Ophthalmology, Others), Origin (Murine Antibodies, Human Antibodies, Humanized Antibodies, Chimeric Antibodies, Others), Target (TNF, CD20, HER2, VEGF, EGFR, PD-1, PD-L1, TNFSF11, IL12/IL23, IL17, IL6, Others) Players and Region - Global Market Outlook to 2030

Monoclonal Antibodies Drug Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 5.7%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Monoclonal Antibodies Drug Market Scope
Monoclonal antibodies drugs are laboratory produced drugs designed to bind the specific receptor on cells surface. They are derived by cell division of a single parent cell. Growing prevalence of chronic disease has led to rise in adoption of monoclonal antibodies drug as it identifies and fix antigens thereby protecting against disease. Introduction of new approved drugs is the other opportunity where manufacturers can cash on.

According to AMA, the Global Monoclonal Antibodies Drug market is expected to see growth rate of 5.7%

Market players are focusing on partnerships, collaborations, and new product launches in order to increase their offerings in the notching machines market. In addition, companies are focusing on increasing their client base to strengthen market position and to enhance product offerings. Research Analyst at AMA estimates that American and Chinese Players will contribute to the maximum growth of Global Monoclonal Antibodies Drug market throughout the predicted period.

Roche Pharmaceuticals (Switzerland), Johnson & Johnson (United States), Merck & Co Inc. (United States), Novartis (Switzerland), AbbVie (United States), Amgen (United States), Eli Lilly and Company (United States), Pfizer (United States), Seattle Genetics (United States), Stemcentrx, Inc (united States) and Takeda Pharmaceutical Company (Japan) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are BIOTECH Pharmaceutical Co., Ltd. (China), Chengdu Taihe Health Technology Group Inc.,Ltd. (China), Genmab (Denmark), GlaxoSmithKline (United Kingdom), Human Genome Sciences (United States), Shanghai Medipharm Biotech Co.,Ltd. (China), Zhejiang Hisun Pharmaceutical Co., Ltd. (China) and Yunnan Walvax Biotechnology Co, Ltd. (China).

Segmentation Overview
The study have segmented the market of Global Monoclonal Antibodies Drug market , by Application (Oncology, Autoimmune, Inflammatory Diseases, Respiratory Diseases, Ophthalmology and Others) and Region with country level break-up.

On the basis of geography, the market of Monoclonal Antibodies Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Influencing Trend:
Growing Awareness Among Patients Regarding Importance of Monoclonal Antibodies Drug

Market Growth Drivers:
Growing Cases of Immunological Disorders and Other Chronic Diseases and Advancement in Next Generation Sequencing Techniques

Challenges:
Stringent Regulatory Frameworks Regarding Manufacturing of Monoclonal Antibodies Drug and Use of Monoclonal Antibodies Drug as a Injectable Medications

Restraints:
High Cost of Monoclonal Antibodies Drug and Nature Specific and Limited Target of Monoclonal Antibodies Drug

Opportunities:
Increasing Spending from Government in Treatment of Cancer and Others Chronic Disease

Market Leaders and their Expansionary Development Strategies
In September 2023, Health and Human Services (HHS) announces new details of its agreement with Regeneron to extend its public-private partnership to develop life-saving monoclonal antibodies as part of Project NextGen enhancing our preparedness for COVID-19 strains and variants. The HHS is committed to lowering drug costs for all Americans. As part of that commitment, HHS and Regeneron announced an extension of their long-standing partnership to develop life-saving monoclonal antibodies
In March 2024, Roche Pharma India on Tuesday launched Vabysmo (faricimab) for the treatment of neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME) in India. With this product, the pharma major has forayed into the Ophthalmology space. Neovascular AMD and DME are two leading causes of vision loss worldwide.


Key Target Audience
Monoclonal Antibodies Drug Manufacturers, Suppliers/Distributors, End-users Industries, Market and Research Firms, Government Organizations and Others

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Report Objectives / Segmentation Covered

By Application
  • Oncology
  • Autoimmune
  • Inflammatory Diseases
  • Respiratory Diseases
  • Ophthalmology
  • Others
By Origin
  • Murine Antibodies
  • Human Antibodies
  • Humanized Antibodies
  • Chimeric Antibodies
  • Others

By Target
  • TNF
  • CD20
  • HER2
  • VEGF
  • EGFR
  • PD-1
  • PD-L1
  • TNFSF11
  • IL12/IL23
  • IL17
  • IL6
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Cases of Immunological Disorders and Other Chronic Diseases
      • 3.2.2. Advancement in Next Generation Sequencing Techniques
    • 3.3. Market Challenges
      • 3.3.1. Stringent Regulatory Frameworks Regarding Manufacturing of Monoclonal Antibodies Drug
      • 3.3.2. Use of Monoclonal Antibodies Drug as a Injectable Medications
    • 3.4. Market Trends
      • 3.4.1. Growing Awareness Among Patients Regarding Importance of Monoclonal Antibodies Drug
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Monoclonal Antibodies Drug, by Application, Origin, Target and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Monoclonal Antibodies Drug (Value)
      • 5.2.1. Global Monoclonal Antibodies Drug by: Application (Value)
        • 5.2.1.1. Oncology
        • 5.2.1.2. Autoimmune
        • 5.2.1.3. Inflammatory Diseases
        • 5.2.1.4. Respiratory Diseases
        • 5.2.1.5. Ophthalmology
        • 5.2.1.6. Others
      • 5.2.2. Global Monoclonal Antibodies Drug by: Origin (Value)
        • 5.2.2.1. Murine Antibodies
        • 5.2.2.2. Human Antibodies
        • 5.2.2.3. Humanized Antibodies
        • 5.2.2.4. Chimeric Antibodies
        • 5.2.2.5. Others
      • 5.2.3. Global Monoclonal Antibodies Drug by: Target (Value)
        • 5.2.3.1. TNF
        • 5.2.3.2. CD20
        • 5.2.3.3. HER2
        • 5.2.3.4. VEGF
        • 5.2.3.5. EGFR
        • 5.2.3.6. PD-1
        • 5.2.3.7. PD-L1
        • 5.2.3.8. TNFSF11
        • 5.2.3.9. IL12/IL23
        • 5.2.3.10. IL17
        • 5.2.3.11. IL6
        • 5.2.3.12. Others
      • 5.2.4. Global Monoclonal Antibodies Drug Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Monoclonal Antibodies Drug (Price)
  • 6. Monoclonal Antibodies Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Roche Pharmaceuticals (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Johnson & Johnson (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck & Co Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Novartis (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. AbbVie (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Amgen (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Eli Lilly and Company (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Pfizer (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Seattle Genetics (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Stemcentrx, Inc (united States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Takeda Pharmaceutical Company (Japan)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Monoclonal Antibodies Drug Sale, by Application, Origin, Target and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Monoclonal Antibodies Drug (Value)
      • 7.2.1. Global Monoclonal Antibodies Drug by: Application (Value)
        • 7.2.1.1. Oncology
        • 7.2.1.2. Autoimmune
        • 7.2.1.3. Inflammatory Diseases
        • 7.2.1.4. Respiratory Diseases
        • 7.2.1.5. Ophthalmology
        • 7.2.1.6. Others
      • 7.2.2. Global Monoclonal Antibodies Drug by: Origin (Value)
        • 7.2.2.1. Murine Antibodies
        • 7.2.2.2. Human Antibodies
        • 7.2.2.3. Humanized Antibodies
        • 7.2.2.4. Chimeric Antibodies
        • 7.2.2.5. Others
      • 7.2.3. Global Monoclonal Antibodies Drug by: Target (Value)
        • 7.2.3.1. TNF
        • 7.2.3.2. CD20
        • 7.2.3.3. HER2
        • 7.2.3.4. VEGF
        • 7.2.3.5. EGFR
        • 7.2.3.6. PD-1
        • 7.2.3.7. PD-L1
        • 7.2.3.8. TNFSF11
        • 7.2.3.9. IL12/IL23
        • 7.2.3.10. IL17
        • 7.2.3.11. IL6
        • 7.2.3.12. Others
      • 7.2.4. Global Monoclonal Antibodies Drug Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Monoclonal Antibodies Drug (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Monoclonal Antibodies Drug: by Application(USD Million)
  • Table 2. Monoclonal Antibodies Drug Oncology , by Region USD Million (2018-2023)
  • Table 3. Monoclonal Antibodies Drug Autoimmune , by Region USD Million (2018-2023)
  • Table 4. Monoclonal Antibodies Drug Inflammatory Diseases , by Region USD Million (2018-2023)
  • Table 5. Monoclonal Antibodies Drug Respiratory Diseases , by Region USD Million (2018-2023)
  • Table 6. Monoclonal Antibodies Drug Ophthalmology , by Region USD Million (2018-2023)
  • Table 7. Monoclonal Antibodies Drug Others , by Region USD Million (2018-2023)
  • Table 8. Monoclonal Antibodies Drug: by Origin(USD Million)
  • Table 9. Monoclonal Antibodies Drug Murine Antibodies , by Region USD Million (2018-2023)
  • Table 10. Monoclonal Antibodies Drug Human Antibodies , by Region USD Million (2018-2023)
  • Table 11. Monoclonal Antibodies Drug Humanized Antibodies , by Region USD Million (2018-2023)
  • Table 12. Monoclonal Antibodies Drug Chimeric Antibodies , by Region USD Million (2018-2023)
  • Table 13. Monoclonal Antibodies Drug Others , by Region USD Million (2018-2023)
  • Table 14. Monoclonal Antibodies Drug: by Target(USD Million)
  • Table 15. Monoclonal Antibodies Drug TNF , by Region USD Million (2018-2023)
  • Table 16. Monoclonal Antibodies Drug CD20 , by Region USD Million (2018-2023)
  • Table 17. Monoclonal Antibodies Drug HER2 , by Region USD Million (2018-2023)
  • Table 18. Monoclonal Antibodies Drug VEGF , by Region USD Million (2018-2023)
  • Table 19. Monoclonal Antibodies Drug EGFR , by Region USD Million (2018-2023)
  • Table 20. Monoclonal Antibodies Drug PD-1 , by Region USD Million (2018-2023)
  • Table 21. Monoclonal Antibodies Drug PD-L1 , by Region USD Million (2018-2023)
  • Table 22. Monoclonal Antibodies Drug TNFSF11 , by Region USD Million (2018-2023)
  • Table 23. Monoclonal Antibodies Drug IL12/IL23 , by Region USD Million (2018-2023)
  • Table 24. Monoclonal Antibodies Drug IL17 , by Region USD Million (2018-2023)
  • Table 25. Monoclonal Antibodies Drug IL6 , by Region USD Million (2018-2023)
  • Table 26. Monoclonal Antibodies Drug Others , by Region USD Million (2018-2023)
  • Table 27. South America Monoclonal Antibodies Drug, by Country USD Million (2018-2023)
  • Table 28. South America Monoclonal Antibodies Drug, by Application USD Million (2018-2023)
  • Table 29. South America Monoclonal Antibodies Drug, by Origin USD Million (2018-2023)
  • Table 30. South America Monoclonal Antibodies Drug, by Target USD Million (2018-2023)
  • Table 31. Brazil Monoclonal Antibodies Drug, by Application USD Million (2018-2023)
  • Table 32. Brazil Monoclonal Antibodies Drug, by Origin USD Million (2018-2023)
  • Table 33. Brazil Monoclonal Antibodies Drug, by Target USD Million (2018-2023)
  • Table 34. Argentina Monoclonal Antibodies Drug, by Application USD Million (2018-2023)
  • Table 35. Argentina Monoclonal Antibodies Drug, by Origin USD Million (2018-2023)
  • Table 36. Argentina Monoclonal Antibodies Drug, by Target USD Million (2018-2023)
  • Table 37. Rest of South America Monoclonal Antibodies Drug, by Application USD Million (2018-2023)
  • Table 38. Rest of South America Monoclonal Antibodies Drug, by Origin USD Million (2018-2023)
  • Table 39. Rest of South America Monoclonal Antibodies Drug, by Target USD Million (2018-2023)
  • Table 40. Asia Pacific Monoclonal Antibodies Drug, by Country USD Million (2018-2023)
  • Table 41. Asia Pacific Monoclonal Antibodies Drug, by Application USD Million (2018-2023)
  • Table 42. Asia Pacific Monoclonal Antibodies Drug, by Origin USD Million (2018-2023)
  • Table 43. Asia Pacific Monoclonal Antibodies Drug, by Target USD Million (2018-2023)
  • Table 44. China Monoclonal Antibodies Drug, by Application USD Million (2018-2023)
  • Table 45. China Monoclonal Antibodies Drug, by Origin USD Million (2018-2023)
  • Table 46. China Monoclonal Antibodies Drug, by Target USD Million (2018-2023)
  • Table 47. Japan Monoclonal Antibodies Drug, by Application USD Million (2018-2023)
  • Table 48. Japan Monoclonal Antibodies Drug, by Origin USD Million (2018-2023)
  • Table 49. Japan Monoclonal Antibodies Drug, by Target USD Million (2018-2023)
  • Table 50. India Monoclonal Antibodies Drug, by Application USD Million (2018-2023)
  • Table 51. India Monoclonal Antibodies Drug, by Origin USD Million (2018-2023)
  • Table 52. India Monoclonal Antibodies Drug, by Target USD Million (2018-2023)
  • Table 53. South Korea Monoclonal Antibodies Drug, by Application USD Million (2018-2023)
  • Table 54. South Korea Monoclonal Antibodies Drug, by Origin USD Million (2018-2023)
  • Table 55. South Korea Monoclonal Antibodies Drug, by Target USD Million (2018-2023)
  • Table 56. Taiwan Monoclonal Antibodies Drug, by Application USD Million (2018-2023)
  • Table 57. Taiwan Monoclonal Antibodies Drug, by Origin USD Million (2018-2023)
  • Table 58. Taiwan Monoclonal Antibodies Drug, by Target USD Million (2018-2023)
  • Table 59. Australia Monoclonal Antibodies Drug, by Application USD Million (2018-2023)
  • Table 60. Australia Monoclonal Antibodies Drug, by Origin USD Million (2018-2023)
  • Table 61. Australia Monoclonal Antibodies Drug, by Target USD Million (2018-2023)
  • Table 62. Rest of Asia-Pacific Monoclonal Antibodies Drug, by Application USD Million (2018-2023)
  • Table 63. Rest of Asia-Pacific Monoclonal Antibodies Drug, by Origin USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Monoclonal Antibodies Drug, by Target USD Million (2018-2023)
  • Table 65. Europe Monoclonal Antibodies Drug, by Country USD Million (2018-2023)
  • Table 66. Europe Monoclonal Antibodies Drug, by Application USD Million (2018-2023)
  • Table 67. Europe Monoclonal Antibodies Drug, by Origin USD Million (2018-2023)
  • Table 68. Europe Monoclonal Antibodies Drug, by Target USD Million (2018-2023)
  • Table 69. Germany Monoclonal Antibodies Drug, by Application USD Million (2018-2023)
  • Table 70. Germany Monoclonal Antibodies Drug, by Origin USD Million (2018-2023)
  • Table 71. Germany Monoclonal Antibodies Drug, by Target USD Million (2018-2023)
  • Table 72. France Monoclonal Antibodies Drug, by Application USD Million (2018-2023)
  • Table 73. France Monoclonal Antibodies Drug, by Origin USD Million (2018-2023)
  • Table 74. France Monoclonal Antibodies Drug, by Target USD Million (2018-2023)
  • Table 75. Italy Monoclonal Antibodies Drug, by Application USD Million (2018-2023)
  • Table 76. Italy Monoclonal Antibodies Drug, by Origin USD Million (2018-2023)
  • Table 77. Italy Monoclonal Antibodies Drug, by Target USD Million (2018-2023)
  • Table 78. United Kingdom Monoclonal Antibodies Drug, by Application USD Million (2018-2023)
  • Table 79. United Kingdom Monoclonal Antibodies Drug, by Origin USD Million (2018-2023)
  • Table 80. United Kingdom Monoclonal Antibodies Drug, by Target USD Million (2018-2023)
  • Table 81. Netherlands Monoclonal Antibodies Drug, by Application USD Million (2018-2023)
  • Table 82. Netherlands Monoclonal Antibodies Drug, by Origin USD Million (2018-2023)
  • Table 83. Netherlands Monoclonal Antibodies Drug, by Target USD Million (2018-2023)
  • Table 84. Rest of Europe Monoclonal Antibodies Drug, by Application USD Million (2018-2023)
  • Table 85. Rest of Europe Monoclonal Antibodies Drug, by Origin USD Million (2018-2023)
  • Table 86. Rest of Europe Monoclonal Antibodies Drug, by Target USD Million (2018-2023)
  • Table 87. MEA Monoclonal Antibodies Drug, by Country USD Million (2018-2023)
  • Table 88. MEA Monoclonal Antibodies Drug, by Application USD Million (2018-2023)
  • Table 89. MEA Monoclonal Antibodies Drug, by Origin USD Million (2018-2023)
  • Table 90. MEA Monoclonal Antibodies Drug, by Target USD Million (2018-2023)
  • Table 91. Middle East Monoclonal Antibodies Drug, by Application USD Million (2018-2023)
  • Table 92. Middle East Monoclonal Antibodies Drug, by Origin USD Million (2018-2023)
  • Table 93. Middle East Monoclonal Antibodies Drug, by Target USD Million (2018-2023)
  • Table 94. Africa Monoclonal Antibodies Drug, by Application USD Million (2018-2023)
  • Table 95. Africa Monoclonal Antibodies Drug, by Origin USD Million (2018-2023)
  • Table 96. Africa Monoclonal Antibodies Drug, by Target USD Million (2018-2023)
  • Table 97. North America Monoclonal Antibodies Drug, by Country USD Million (2018-2023)
  • Table 98. North America Monoclonal Antibodies Drug, by Application USD Million (2018-2023)
  • Table 99. North America Monoclonal Antibodies Drug, by Origin USD Million (2018-2023)
  • Table 100. North America Monoclonal Antibodies Drug, by Target USD Million (2018-2023)
  • Table 101. United States Monoclonal Antibodies Drug, by Application USD Million (2018-2023)
  • Table 102. United States Monoclonal Antibodies Drug, by Origin USD Million (2018-2023)
  • Table 103. United States Monoclonal Antibodies Drug, by Target USD Million (2018-2023)
  • Table 104. Canada Monoclonal Antibodies Drug, by Application USD Million (2018-2023)
  • Table 105. Canada Monoclonal Antibodies Drug, by Origin USD Million (2018-2023)
  • Table 106. Canada Monoclonal Antibodies Drug, by Target USD Million (2018-2023)
  • Table 107. Mexico Monoclonal Antibodies Drug, by Application USD Million (2018-2023)
  • Table 108. Mexico Monoclonal Antibodies Drug, by Origin USD Million (2018-2023)
  • Table 109. Mexico Monoclonal Antibodies Drug, by Target USD Million (2018-2023)
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. Company Basic Information, Sales Area and Its Competitors
  • Table 114. Company Basic Information, Sales Area and Its Competitors
  • Table 115. Company Basic Information, Sales Area and Its Competitors
  • Table 116. Company Basic Information, Sales Area and Its Competitors
  • Table 117. Company Basic Information, Sales Area and Its Competitors
  • Table 118. Company Basic Information, Sales Area and Its Competitors
  • Table 119. Company Basic Information, Sales Area and Its Competitors
  • Table 120. Company Basic Information, Sales Area and Its Competitors
  • Table 121. Monoclonal Antibodies Drug: by Application(USD Million)
  • Table 122. Monoclonal Antibodies Drug Oncology , by Region USD Million (2025-2030)
  • Table 123. Monoclonal Antibodies Drug Autoimmune , by Region USD Million (2025-2030)
  • Table 124. Monoclonal Antibodies Drug Inflammatory Diseases , by Region USD Million (2025-2030)
  • Table 125. Monoclonal Antibodies Drug Respiratory Diseases , by Region USD Million (2025-2030)
  • Table 126. Monoclonal Antibodies Drug Ophthalmology , by Region USD Million (2025-2030)
  • Table 127. Monoclonal Antibodies Drug Others , by Region USD Million (2025-2030)
  • Table 128. Monoclonal Antibodies Drug: by Origin(USD Million)
  • Table 129. Monoclonal Antibodies Drug Murine Antibodies , by Region USD Million (2025-2030)
  • Table 130. Monoclonal Antibodies Drug Human Antibodies , by Region USD Million (2025-2030)
  • Table 131. Monoclonal Antibodies Drug Humanized Antibodies , by Region USD Million (2025-2030)
  • Table 132. Monoclonal Antibodies Drug Chimeric Antibodies , by Region USD Million (2025-2030)
  • Table 133. Monoclonal Antibodies Drug Others , by Region USD Million (2025-2030)
  • Table 134. Monoclonal Antibodies Drug: by Target(USD Million)
  • Table 135. Monoclonal Antibodies Drug TNF , by Region USD Million (2025-2030)
  • Table 136. Monoclonal Antibodies Drug CD20 , by Region USD Million (2025-2030)
  • Table 137. Monoclonal Antibodies Drug HER2 , by Region USD Million (2025-2030)
  • Table 138. Monoclonal Antibodies Drug VEGF , by Region USD Million (2025-2030)
  • Table 139. Monoclonal Antibodies Drug EGFR , by Region USD Million (2025-2030)
  • Table 140. Monoclonal Antibodies Drug PD-1 , by Region USD Million (2025-2030)
  • Table 141. Monoclonal Antibodies Drug PD-L1 , by Region USD Million (2025-2030)
  • Table 142. Monoclonal Antibodies Drug TNFSF11 , by Region USD Million (2025-2030)
  • Table 143. Monoclonal Antibodies Drug IL12/IL23 , by Region USD Million (2025-2030)
  • Table 144. Monoclonal Antibodies Drug IL17 , by Region USD Million (2025-2030)
  • Table 145. Monoclonal Antibodies Drug IL6 , by Region USD Million (2025-2030)
  • Table 146. Monoclonal Antibodies Drug Others , by Region USD Million (2025-2030)
  • Table 147. South America Monoclonal Antibodies Drug, by Country USD Million (2025-2030)
  • Table 148. South America Monoclonal Antibodies Drug, by Application USD Million (2025-2030)
  • Table 149. South America Monoclonal Antibodies Drug, by Origin USD Million (2025-2030)
  • Table 150. South America Monoclonal Antibodies Drug, by Target USD Million (2025-2030)
  • Table 151. Brazil Monoclonal Antibodies Drug, by Application USD Million (2025-2030)
  • Table 152. Brazil Monoclonal Antibodies Drug, by Origin USD Million (2025-2030)
  • Table 153. Brazil Monoclonal Antibodies Drug, by Target USD Million (2025-2030)
  • Table 154. Argentina Monoclonal Antibodies Drug, by Application USD Million (2025-2030)
  • Table 155. Argentina Monoclonal Antibodies Drug, by Origin USD Million (2025-2030)
  • Table 156. Argentina Monoclonal Antibodies Drug, by Target USD Million (2025-2030)
  • Table 157. Rest of South America Monoclonal Antibodies Drug, by Application USD Million (2025-2030)
  • Table 158. Rest of South America Monoclonal Antibodies Drug, by Origin USD Million (2025-2030)
  • Table 159. Rest of South America Monoclonal Antibodies Drug, by Target USD Million (2025-2030)
  • Table 160. Asia Pacific Monoclonal Antibodies Drug, by Country USD Million (2025-2030)
  • Table 161. Asia Pacific Monoclonal Antibodies Drug, by Application USD Million (2025-2030)
  • Table 162. Asia Pacific Monoclonal Antibodies Drug, by Origin USD Million (2025-2030)
  • Table 163. Asia Pacific Monoclonal Antibodies Drug, by Target USD Million (2025-2030)
  • Table 164. China Monoclonal Antibodies Drug, by Application USD Million (2025-2030)
  • Table 165. China Monoclonal Antibodies Drug, by Origin USD Million (2025-2030)
  • Table 166. China Monoclonal Antibodies Drug, by Target USD Million (2025-2030)
  • Table 167. Japan Monoclonal Antibodies Drug, by Application USD Million (2025-2030)
  • Table 168. Japan Monoclonal Antibodies Drug, by Origin USD Million (2025-2030)
  • Table 169. Japan Monoclonal Antibodies Drug, by Target USD Million (2025-2030)
  • Table 170. India Monoclonal Antibodies Drug, by Application USD Million (2025-2030)
  • Table 171. India Monoclonal Antibodies Drug, by Origin USD Million (2025-2030)
  • Table 172. India Monoclonal Antibodies Drug, by Target USD Million (2025-2030)
  • Table 173. South Korea Monoclonal Antibodies Drug, by Application USD Million (2025-2030)
  • Table 174. South Korea Monoclonal Antibodies Drug, by Origin USD Million (2025-2030)
  • Table 175. South Korea Monoclonal Antibodies Drug, by Target USD Million (2025-2030)
  • Table 176. Taiwan Monoclonal Antibodies Drug, by Application USD Million (2025-2030)
  • Table 177. Taiwan Monoclonal Antibodies Drug, by Origin USD Million (2025-2030)
  • Table 178. Taiwan Monoclonal Antibodies Drug, by Target USD Million (2025-2030)
  • Table 179. Australia Monoclonal Antibodies Drug, by Application USD Million (2025-2030)
  • Table 180. Australia Monoclonal Antibodies Drug, by Origin USD Million (2025-2030)
  • Table 181. Australia Monoclonal Antibodies Drug, by Target USD Million (2025-2030)
  • Table 182. Rest of Asia-Pacific Monoclonal Antibodies Drug, by Application USD Million (2025-2030)
  • Table 183. Rest of Asia-Pacific Monoclonal Antibodies Drug, by Origin USD Million (2025-2030)
  • Table 184. Rest of Asia-Pacific Monoclonal Antibodies Drug, by Target USD Million (2025-2030)
  • Table 185. Europe Monoclonal Antibodies Drug, by Country USD Million (2025-2030)
  • Table 186. Europe Monoclonal Antibodies Drug, by Application USD Million (2025-2030)
  • Table 187. Europe Monoclonal Antibodies Drug, by Origin USD Million (2025-2030)
  • Table 188. Europe Monoclonal Antibodies Drug, by Target USD Million (2025-2030)
  • Table 189. Germany Monoclonal Antibodies Drug, by Application USD Million (2025-2030)
  • Table 190. Germany Monoclonal Antibodies Drug, by Origin USD Million (2025-2030)
  • Table 191. Germany Monoclonal Antibodies Drug, by Target USD Million (2025-2030)
  • Table 192. France Monoclonal Antibodies Drug, by Application USD Million (2025-2030)
  • Table 193. France Monoclonal Antibodies Drug, by Origin USD Million (2025-2030)
  • Table 194. France Monoclonal Antibodies Drug, by Target USD Million (2025-2030)
  • Table 195. Italy Monoclonal Antibodies Drug, by Application USD Million (2025-2030)
  • Table 196. Italy Monoclonal Antibodies Drug, by Origin USD Million (2025-2030)
  • Table 197. Italy Monoclonal Antibodies Drug, by Target USD Million (2025-2030)
  • Table 198. United Kingdom Monoclonal Antibodies Drug, by Application USD Million (2025-2030)
  • Table 199. United Kingdom Monoclonal Antibodies Drug, by Origin USD Million (2025-2030)
  • Table 200. United Kingdom Monoclonal Antibodies Drug, by Target USD Million (2025-2030)
  • Table 201. Netherlands Monoclonal Antibodies Drug, by Application USD Million (2025-2030)
  • Table 202. Netherlands Monoclonal Antibodies Drug, by Origin USD Million (2025-2030)
  • Table 203. Netherlands Monoclonal Antibodies Drug, by Target USD Million (2025-2030)
  • Table 204. Rest of Europe Monoclonal Antibodies Drug, by Application USD Million (2025-2030)
  • Table 205. Rest of Europe Monoclonal Antibodies Drug, by Origin USD Million (2025-2030)
  • Table 206. Rest of Europe Monoclonal Antibodies Drug, by Target USD Million (2025-2030)
  • Table 207. MEA Monoclonal Antibodies Drug, by Country USD Million (2025-2030)
  • Table 208. MEA Monoclonal Antibodies Drug, by Application USD Million (2025-2030)
  • Table 209. MEA Monoclonal Antibodies Drug, by Origin USD Million (2025-2030)
  • Table 210. MEA Monoclonal Antibodies Drug, by Target USD Million (2025-2030)
  • Table 211. Middle East Monoclonal Antibodies Drug, by Application USD Million (2025-2030)
  • Table 212. Middle East Monoclonal Antibodies Drug, by Origin USD Million (2025-2030)
  • Table 213. Middle East Monoclonal Antibodies Drug, by Target USD Million (2025-2030)
  • Table 214. Africa Monoclonal Antibodies Drug, by Application USD Million (2025-2030)
  • Table 215. Africa Monoclonal Antibodies Drug, by Origin USD Million (2025-2030)
  • Table 216. Africa Monoclonal Antibodies Drug, by Target USD Million (2025-2030)
  • Table 217. North America Monoclonal Antibodies Drug, by Country USD Million (2025-2030)
  • Table 218. North America Monoclonal Antibodies Drug, by Application USD Million (2025-2030)
  • Table 219. North America Monoclonal Antibodies Drug, by Origin USD Million (2025-2030)
  • Table 220. North America Monoclonal Antibodies Drug, by Target USD Million (2025-2030)
  • Table 221. United States Monoclonal Antibodies Drug, by Application USD Million (2025-2030)
  • Table 222. United States Monoclonal Antibodies Drug, by Origin USD Million (2025-2030)
  • Table 223. United States Monoclonal Antibodies Drug, by Target USD Million (2025-2030)
  • Table 224. Canada Monoclonal Antibodies Drug, by Application USD Million (2025-2030)
  • Table 225. Canada Monoclonal Antibodies Drug, by Origin USD Million (2025-2030)
  • Table 226. Canada Monoclonal Antibodies Drug, by Target USD Million (2025-2030)
  • Table 227. Mexico Monoclonal Antibodies Drug, by Application USD Million (2025-2030)
  • Table 228. Mexico Monoclonal Antibodies Drug, by Origin USD Million (2025-2030)
  • Table 229. Mexico Monoclonal Antibodies Drug, by Target USD Million (2025-2030)
  • Table 230. Research Programs/Design for This Report
  • Table 231. Key Data Information from Secondary Sources
  • Table 232. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Monoclonal Antibodies Drug: by Application USD Million (2018-2023)
  • Figure 5. Global Monoclonal Antibodies Drug: by Origin USD Million (2018-2023)
  • Figure 6. Global Monoclonal Antibodies Drug: by Target USD Million (2018-2023)
  • Figure 7. South America Monoclonal Antibodies Drug Share (%), by Country
  • Figure 8. Asia Pacific Monoclonal Antibodies Drug Share (%), by Country
  • Figure 9. Europe Monoclonal Antibodies Drug Share (%), by Country
  • Figure 10. MEA Monoclonal Antibodies Drug Share (%), by Country
  • Figure 11. North America Monoclonal Antibodies Drug Share (%), by Country
  • Figure 12. Global Monoclonal Antibodies Drug share by Players 2023 (%)
  • Figure 13. Global Monoclonal Antibodies Drug share by Players (Top 3) 2023(%)
  • Figure 14. Global Monoclonal Antibodies Drug share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Roche Pharmaceuticals (Switzerland) Revenue, Net Income and Gross profit
  • Figure 17. Roche Pharmaceuticals (Switzerland) Revenue: by Geography 2023
  • Figure 18. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 19. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 20. Merck & Co Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Merck & Co Inc. (United States) Revenue: by Geography 2023
  • Figure 22. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 23. Novartis (Switzerland) Revenue: by Geography 2023
  • Figure 24. AbbVie (United States) Revenue, Net Income and Gross profit
  • Figure 25. AbbVie (United States) Revenue: by Geography 2023
  • Figure 26. Amgen (United States) Revenue, Net Income and Gross profit
  • Figure 27. Amgen (United States) Revenue: by Geography 2023
  • Figure 28. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 29. Eli Lilly and Company (United States) Revenue: by Geography 2023
  • Figure 30. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 31. Pfizer (United States) Revenue: by Geography 2023
  • Figure 32. Seattle Genetics (United States) Revenue, Net Income and Gross profit
  • Figure 33. Seattle Genetics (United States) Revenue: by Geography 2023
  • Figure 34. Stemcentrx, Inc (united States) Revenue, Net Income and Gross profit
  • Figure 35. Stemcentrx, Inc (united States) Revenue: by Geography 2023
  • Figure 36. Takeda Pharmaceutical Company (Japan) Revenue, Net Income and Gross profit
  • Figure 37. Takeda Pharmaceutical Company (Japan) Revenue: by Geography 2023
  • Figure 38. Global Monoclonal Antibodies Drug: by Application USD Million (2025-2030)
  • Figure 39. Global Monoclonal Antibodies Drug: by Origin USD Million (2025-2030)
  • Figure 40. Global Monoclonal Antibodies Drug: by Target USD Million (2025-2030)
  • Figure 41. South America Monoclonal Antibodies Drug Share (%), by Country
  • Figure 42. Asia Pacific Monoclonal Antibodies Drug Share (%), by Country
  • Figure 43. Europe Monoclonal Antibodies Drug Share (%), by Country
  • Figure 44. MEA Monoclonal Antibodies Drug Share (%), by Country
  • Figure 45. North America Monoclonal Antibodies Drug Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Roche Pharmaceuticals (Switzerland)
  • Johnson & Johnson (United States)
  • Merck & Co Inc. (United States)
  • Novartis (Switzerland)
  • AbbVie (United States)
  • Amgen (United States)
  • Eli Lilly and Company (United States)
  • Pfizer (United States)
  • Seattle Genetics (United States)
  • Stemcentrx, Inc (united States)
  • Takeda Pharmaceutical Company (Japan)
Additional players considered in the study are as follows:
BIOTECH Pharmaceutical Co., Ltd. (China) , Chengdu Taihe Health Technology Group Inc.,Ltd. (China) , Genmab (Denmark) , GlaxoSmithKline (United Kingdom) , Human Genome Sciences (United States) , Shanghai Medipharm Biotech Co.,Ltd. (China) , Zhejiang Hisun Pharmaceutical Co., Ltd. (China) , Yunnan Walvax Biotechnology Co, Ltd. (China)
Select User Access Type

Key Highlights of Report


Apr 2024 205 Pages 81 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Monoclonal Antibodies Drug Market Quantitative research analysis
Global Monoclonal Antibodies Drug Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Monoclonal Antibodies Drug study can be customized to meet your requirements. The market size breakdown by type, by end-use application.
The Monoclonal Antibodies Drug Market is gaining popularity and expected to see strong valuation by 2030 .
According to AMA, the Global Monoclonal Antibodies Drug market is expected to see growth rate of xx%.
The Monoclonal Antibodies Drug market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete of companies available in our research coverage.

Know More About Global Monoclonal Antibodies Drug Market Report?

Have a Query? Click Here

Other Related Reports

Medical Skincare Comprehensive Study by Type (Cleansers, Toners, Scrubs & Masks, Serums, Moisturizers, Eye Creams, SPF, Others), Application (Acne, Anti-Aging, Brightening, Sensitive Skin, Dry Skin, ...
$ 3750
Weight Loss Therapeutics Comprehensive Study by Therapy (Intensive Behavioural Therapy, Self-Monitoring Therapy), End Users (Hospitals, Therapy Clinics, Pharmaceuticals Organization), Distribution Ch...
$ 3650
Genitourinary System Treatment Comprehensive Study by Type (OTC, Rx Drugs), Application (Hospital, Clinics, Ambulatory Surgical Centers), Drugs (Hormonal Therapy, Impotence Agents, Uterine Relaxants,...
$ 3750
Biliary Tumor Comprehensive Study by Type (Mecine, Surgery, Other), Application (Hospitals, Clinics, Other) Players and Region - Global Market Outlook to 2029
$ 3500
Neutropenia Treatment Comprehensive Study by Type (Granulocyte -colony-stimulating factor (G-CSF), Antibiotics, Antifungal drugs), Disease Type (Cyclic neutropenia, Kostmann’s syndrome, Chronic idiop...
$ 3750
Omnitrope Comprehensive Study by Type (Injection, Oral), Application (Hospital, Medical Center, Others), Medical Conditions (Hormone Deficiency, Chronic Kidney Disease, Idiopathic Short Stature, Noon...
$ 3450